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Abstract
Identifying patients who are potential placebo responders has major implications for clinical practice and trial design.
Catechol-O-methyltransferase (COMT), an important enzyme in dopamine catabolism plays a key role in processes
associated with the placebo effect such as reward, pain, memory and learning. We hypothesized that the COMT functional
val158met polymorphism, was a predictor of placebo effects and tested our hypothesis in a subset of 104 patients from a
previously reported randomized controlled trial in irritable bowel syndrome (IBS). The three treatment arms from this study
were: no-treatment (‘‘waitlist’’), placebo treatment alone (‘‘limited’’) and, placebo treatment ‘‘augmented’’ with a supportive
patient-health care provider interaction. The primary outcome measure was change from baseline in IBS-Symptom Severity
Scale (IBS-SSS) after three weeks of treatment. In a regression model, the number of methionine alleles in COMT val158met
was linearly related to placebo response as measured by changes in IBS-SSS (p=.035). The strongest placebo response
occurred in met/met homozygotes treated in the augmented placebo arm. A smaller met/met associated effect was
observed with limited placebo treatment and there was no effect in the waitlist control. These data support our hypothesis
that the COMT val158met polymorphism is a potential biomarker of placebo response.
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Introduction
Placebo treatments have been shown to lead to clinical
improvement in a broad spectrum of disorders [1]. Although
advances have been made in understanding the neurobiology of
placebo [2], our understanding of the genetic modulators of the
placebo response remains a critical knowledge gap. Identifying the
characteristics of placebo responders and non-responders is key to
managing underlying placebogenic factors for patient benefit and
to optimizing the design and interpretation of clinical trials.
Studies investigating brain activity associated with placebo
response in pain, Parkinson’s disease and depression, point to
dopamine as a possible integrator of the placebo response
[2,3,4,5]. Dopamine is a catecholamine synthesized from tyrosine
by tyrosine hydroxylase and dopamine decarboxylase. Once
synthesized, dopamine is packaged into presynaptic vesicles and
released into the synaptic cleft upon depolarization. Dopamine is
cleared from the synapse either by the dopamine reuptake
transporter (DAT), or degradation by monoamine oxidases A
and B, or catechol-O-methyltransferase (COMT). Whereas
reuptake is the primary mechanism of dopamine clearance in
the striatum, in the prefrontal cortex, DAT is less abundant,
rendering COMT activity critical in regulating prefrontal dopa-
mine signaling [6,7].
Among the genetic polymorphisms in the dopamine pathway,
the COMT val158met polymorphism has been studied most
extensively in clinical trials for its potential association with
treatment responses. COMT val158met, is a G to A transition
leading to amino-acid substitution at codon 158 in the transmem-
brane form of the enzyme [8]. The methionine isoform has
reduced thermostability, resulting in a three to four-fold decrease
in activity relative to the ancestral valine isoform [9]. This
functional polymorphism has been correlated with variations in
memory function [10,11], cognition [12], attentional processing
[13], affect [14], confirmation bias [15], pain processing and
sensitivity [16,17,18,19]. Met/met individuals have higher levels of
performance in cognitive tests, which measure executive function
as well as increased sensitivity to experimental and chronic pain
relative to val/met and val/val individuals [16,19,20,21,22].
Given that COMT has an effect on dopamine levels in the
prefrontal cortex, a brain region activated during placebo
response, we hypothesized that the functional COMT val158met
polymorphism is a placebo response variant. To our knowledge,
no previous study has reported an association between COMT
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(IBS). IBS, a common gastrointestinal disorder affecting 10 to 15%
of North Americans [23,24] is characterized by abdominal pain or
discomfort associated with altered bowel function, bloating, and a
sensation of incomplete evacuation after bowel movements
[25,26]. IBS is a condition known to have a high placebo response
rate and meta-analyses report an average placebo induced global
improvement of approximately 40% [27,28,29].
Previously, our team investigated IBS placebo responses in a
clinical trial which had three arms: 1) a no-treatment arm that
controlled for regression to the mean and normal fluctuations in
illness (‘‘waitlist’’), 2) a placebo treatment arm which used a
validated placebo acupuncture device administered in a business-
like no frills clinical context (‘‘limited placebo’’), and 3) a limited
placebo arm augmented with a supportive warm provider who
expressed confidence in the effectiveness of the treatment
(‘‘augmented placebo’’). Overall, we found a robust clinical
response to the placebo treatments; validated IBS outcome
measures showed augmented placebo was significantly more
effective than limited placebo, which in turn was more effective
than the no-treatment waitlist control [30].
Our parent IBS clinical trial was ideal for the study of genetic
associations with placebo effects because it included a waitlist
(observation alone) control and two different ‘‘doses’’ of placebo
(limited and augmented). The waitlist control allowed for
separation of regression to the mean and the natural waxing and
waning of illness from the effects of placebo treatment. The two
types of placebo interventions, limited and augmented, created a
comparison of incremental components of the placebo effect in a
manner that could be considered analogous to dose dependent.
Here we present the first study to support the hypothesis that the
COMT val158met polymorphism is a potential genetic marker of
placebo response.
Materials and Methods
Study populations
A randomized clinical trial investigating placebo effects in IBS
patients (Trial registration – NCT00065403) was conducted.
Details of the design and outcomes of the trial are provided
elsewhere [30,31]. The 3-week trial enrolled 262 patients (75%
women) $18 years and diagnosed by IBS Rome II criteria score of
.150 on the Irritable Bowel Syndrome Symptom Severity Scale
(IBS-SSS) [32].
Randomization and Interventions
Patients were randomized to one of three treatment arms: (1)
no-treatment control (‘‘waitlist); (2) placebo acupuncture (‘‘limit-
ed’’); (3) placebo acupuncture plus a supportive patient-provider
(‘‘augmented’’). A validated sham acupuncture device was used to
deliver placebo acupuncture in 20 minute sessions, twice weekly
for three weeks.
Ethics Statement
A subgroup of patients (n=112) gave consent for genetic
analysis from blood samples included in this study. The
Institutional Review Board at Beth Israel Deaconess Medical
Center (Boston, MA) approved the main study and the genetic
follow-up study presented here. All studies were conducted in
accordance with the Declaration of Helsinki. Participants provided
written consent for this genetic study. The ethics committee
approved this procedure.
Outcomes
Three validated IBS research measures from the previous trial,
which assessed clinical outcomes, were used in this study. The
primary outcome measure was the IBS-SSS, which consists of five
100-point scales (abdominal pain severity, abdominal pain
frequency, abdominal distention severity, dissatisfaction with
bowel habits, and quality of life disruption) that contribute equally
to the final score, yielding a theoretical range of 0–500 [32].
Higher scores reflected a more severe condition. IBS-SSS was
measured at baseline and after 3 weeks of treatment. Change in
IBS-SSS was determined by subtracting 3-week IBS-SSS score
from baseline IBS-SSS. We selected IBS-SSS as our primary
outcome because the two secondary measures, Adequate Relief
(AR) and the Global Improvement Scale (GIS) did not have
baseline measures. Adequate Relief was assessed by a single
dichotomous question at 3-weeks, which asked: ‘‘Over the past
week have you had adequate relief of your IBS symptoms?’’ [33].
The GIS asked: ‘‘Compared to the way you felt before you entered
the study, have your IBS symptoms over the past 7 days been:
(1)=substantially worse, (2)=moderately worse, (3)=slightly
worse, (4)=no change, (5)=slightly improved, (6)=moderately
improved, or (7)=substantially improved’’ [34,35]. These latter
two measures were considered secondary because they do not have
baseline assessments, thus opening the door to regression artifacts
[36]. To mitigate this problem, we controlled for IBS-SSS baseline
scores in analyses of AR and GIS.
Genotyping
Of the 262 original study participants, 112 gave consent for
genetic screening. Eight patients missing IBS-SSS data at 3-weeks
were excluded from the analyses. Two additional patients were
missing data for AR and GIS and were excluded from analysis of
AR and GIS. Genomic DNA was extracted from whole blood
using Qiagen Blood kit (Valencia, CA) following the manufactur-
er’s protocol. Based on the association of COMT SNP rs4633 with
COMT expression and activity [37], this SNP was genotyped in
addition to rs4680 (val158met). TaqMan SNP Genotyping assays
for rs4680 (val158met) and rs4633 were purchased from Applied
Biosystems, (Foster City, CA). Quantitative PCR was performed at
the Biopolymers Facility at Harvard Medical School, (Boston, MA)
following the manufacturer’s protocol on an Applied Biosystems
7900HT instrument, using SDS version 2.4 software.
Statistical Analysis
Hardy–Weinberg Equilibrium (HWE) and Linkage Disequilib-
rium were calculated using the Online Encyclopedia for Genetic
Epidemiology studies [38,39]. Statistical analyses were performed
using IBM SPSS Statistics version 20 (Chicago, IL).
We used an additive genetic model to investigate the linear
effect of increases in the presence of the COMT met allele. We
created a variable, ‘‘COMT genotype’’, that coded each patient’s
val158met genotype as follows: 1=met/met; 0=val/met;
21=val/val. Using standard coding for polynomial trends, we
used multiple regression to examine linear and quadratic effects of
COMT genotype (number of met alleles) on placebo responses as
measured by changes from baseline IBS-SSS, and on AR and GIS.
We controlled for initial disease severity by including baseline IBS-
SSS as a covariate in the regression models. In addition, we
created variables to test for linear and quadratic effects of
treatment, conceiving these as ascending ‘‘doses’’ of non-specific
effects (waitlist, limited placebo, augmented placebo) to test for
interactions between COMT genotype effects and treatment
received.
COMT Predicts Placebo Effect in IBS
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The clinical and demographic characteristics of the subset of
genotyped patients (n=104) relative to the original clinical trial
(n=262) [30] are shown in Table 1. Age, gender, race and marital
status of the genotyped patients did not differ significantly from the
distribution in the original study; duration, IBS type and baseline
IBS-SSS were also similar. Eighty percent of the genotyped
patients were women and 94% were white. Furthermore there
were no significant differences in demographics and disease
characteristics of genotyped patients across the COMT val158met
genotypes. The number of patients genotyped and analyzed from
each treatment arm (waitlist, 29%; limited, 32%; and augmented,
39%) was similar to the overall distribution in the original trial
(waitlist, 33%; limited, 34%; and augmented, 33%).
Based on its association with rs4680, COMT expression and
enzymatic activity we also genotyped rs4633 [37]. Rs4633 was
found to be in strong linkage disequilibrium with rs4680 (D’ =.94
and r2=.9), such that the two SNPs were almost perfectly
correlated: met/met, val/met and val/val of rs4680 corresponded
to the T/T, T/C and C/C of rs4633. Therefore we focused on
COMT val158met in further analyses. The minor allele frequency
of COMT val158met was 0.46 and the SNP was in Hardy–
Weinberg Equilibrium (p=.502).
In this study, IBS Symptom Severity Scale (IBS-SSS) was our a
priori primary clinical outcome. IBS-SSS is a multidimensional
measure that captures the full spectrum of IBS disease including
abdominal pain severity, abdominal pain frequency, abdominal
distention severity, dissatisfaction with bowel habits, and disrup-
tion in quality of life and has a theoretical range of 0–500 [32].
Both linear and quadratic effects of COMT alleles and
treatment arm (waitlist, limited, augmented) were tested. As there
were no significant main effects or interactions involving quadratic
tests, results reported here are for a trimmed model with only
linear effects and interactions included.
IBS-Symptom Severity Scale (IBS-SSS)
Change in IBS-SSS was associated with a main effect of COMT
genotype (number of met alleles) (Figure 1). Number of COMT
val158met met alleles showed a significant linear effect on IBS-
SSS (beta=0.17; p=.032). Patients with the met/met genotype
had the greatest level of improvement whereas val/val patients
had the least, and val/met patients were intermediate (Figure 1).
As in the original study [30], there was a main effect of treatment
arm on improvement, with patients in the augmented treatment
improving most and those on waitlist improving least (beta=0.19,
p=.019).
These linear effects on IBS-SSS were qualified by significant
interactions between COMT genotype and treatment arm
(beta=0.17; p=.035). COMT predicted responses in only the
augmented placebo arm. In response to a high dose placebo
treatment, patients homozygous for met alleles (met/met), showed
the greatest improvement; val homozygotes (val/val) showed the
least improvement and heterozygote (val/met) patients had an
intermediate response (Figure 2).
Adequate Relief
The secondary validated measure of Adequate Relief uses a
single dichotomous question at 3-weeks which asked: ‘‘Over the
past week have you had adequate relief of your IBS symptoms?’’
[33]. The responses were coded as 0=No, I did not have
Adequate Relief and 1=Yes, I had Adequate Relief. As expected
from the previous study, there was a significant linear effect for
treatment arm (beta =0.32, p=.001), in which patients in the
augmented placebo arm showed most improvement and those in
the waitlist arm showed the least [30]. Although there was no main
effect for COMT genotype, there was a significant interaction
between COMT genotype and treatment arm (beta =0.25,
p=.009). In the augmented placebo arm, the met/met patients
reported an average Adequate Relief score of 0.88 compared to
0.63 for val/met patients and 0.56 for val/val patients (Figure 3).
Conversely, in the waitlist group, val/val patients had an average
score of 0.50, whereas the met/met patients had an average score
of 0.00, that is no met/met patients on the waitlist arm reported
Adequate Relief.
Table 1. Baseline characteristics of genotyped IBS patients compared to participants in the parent randomized clinical trial.
Characteristics
All IBS
patients*
(n=262)
Genotyped
patients
(n=112)
p
value
met/met
(n=20)
val/met
(n=55)
val/val
(n=29)
p
value
Demographics
Age in years (SD) 38 (14) 37 (13) 0.53 40 (12) 36 (13) 38 (14) 0.44
Women (%) 218 (83) 83 (80) 0.51 16 (80) 45 (81) 22 (76) 0.82
White (%) 252 (96) 98 (94) 0.17 20(100) 52 (95) 26 (89) 0.20
Married/living
together (%)
101 (39) 32 (31) 0.42 8 (42) 16 (41) 8 (33) 0.79
IBS symptoms and baseline characteristics
Type of IBS 0.56 0.80
Constipation (%) 74 (28) 35 (34) 5 (25) 21 (39) 9 (31)
Diarrhea (%) 65 (25) 18 (17) 4 (20) 8 (15) 6 (21)
Mixed (%) 139 (53) 40 (38) 11 (55) 25 (46) 14 (48)
Disease for .5 years (%) 103 (39) 63 (61) 0.18 12 (60) 34 (62) 17 (59) 0.96
Baseline IBS-SSS (SD) 273 (73) 270 (66) 0.72 291 (78) 261 (64) 272 (61) 0.23
*Participants in parent clinical trial previously reported [30].
doi:10.1371/journal.pone.0048135.t001
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The other secondary validated measure was Global Improve-
ment Scale (GIS) which asked: ‘‘Compared to the way you felt
before you entered the study, have your IBS symptoms over the
past 7 days been: (1)=substantially worse, (2)=moderately worse,
(3)=slightly worse, (4)=no change, (5)=slightly improved,
(6)=moderately improved, or (7)=substantially improved’’ [34].
As in the case of IBS-SSS and Adequate Relief, there was an
expected significant linear effect for treatment arm (beta =0.31,
p=.002), in which patients in the augmented placebo arm showed
most improvement and those in the waitlist arm showed the least
[30]. There was a trend in improvement associated with COMT
genotype (beta=0.18, p=.063) but no interaction of COMT
genotype with treatment arm (beta=0.07, p=.477).
Discussion
In this study, we demonstrated that IBS patients homozygous
for the COMT val158met methionine allele (met/met) were the
most responsive to placebo treatment. Heterozygous (val/met)
patients showed an intermediate response, and homozygous valine
(val/val) patients showed essentially no placebo mediated symp-
tom improvement. To our knowledge, this is the first study to
demonstrate genetic modulation of true placebo effects disassoci-
ated from changes related to disease natural history and regression
to the mean. It is also the first study to demonstrate a relationship
between different levels of placebo treatment and COMT
genotype.
Our regression analysis showed that as the number of COMT
val158met met alleles increased progressively from 0 to 1 to 2, and
COMT activity decreased, theoretically making more dopamine
available in the prefrontal cortex, placebo responses increased in a
linear fashion. Further, there was a significant interaction between
number of methionine alleles and placebo treatment arm.
Examination of the interactions illustrated in Figures 2 and 3,
showed that the relationship between number of COMT met
alleles and placebo response occurred primarily in the augmented
placebo arm, with a smaller effect in the limited placebo arm, and
no effect (IBS-SSS) or a reverse effect (Adequate Relief) in the
waitlist control arm. Taken together, these results strongly suggest
that COMT val158met, specifically the met/met genotype, is a
potential marker for placebo responders in IBS. Furthermore the
finding that this genotype is associated with a positive outcome
only in groups given a placebo (and not in the waitlist control
group) is of particular importance, as it indicates that it is a
predictor of the placebo effect, not just improvement in general.
To date, the search for placebo biomarkers has been elusive.
The three previous studies we are aware of which looked for a
genetic link to the placebo response lacked the critical no-
treatment control [21,40,41]. Neither of the two studies that
examined the relationship between COMT and placebo response
found a statistically significant relationship [21,41]. The third
study on severe anxiety disorder (SAD) found that polymorphisms
in two serotonin-related genes, the serotonin transporter-linked
polymorphic region (5-HTTLPR) and the G703T polymorphism
Figure 2. Interaction effect of COMT genotype and treatment
arm on change in IBS-SSS. The interaction between COMT genotype
(number of met alleles) and treatment arm was statistically significant
(beta=0.17; p=.035). Regression model included the following
parameters: COMT genotype (number of met alleles), treatment arm,
baseline IBS-SSS and their interaction (COMT genotype x treatment
arm). Error bars indicate the standard error of the mean. N=104.
doi:10.1371/journal.pone.0048135.g002
Figure 3. Interaction effect of COMT genotype and treatment
arm on Adequate Relief. The interaction (COMT genotype x
treatment arm) was statistically significant (beta=0.25; p=.009), but
not COMT genotype (beta=0.01; p=.954). Adequate Relief was
assessed by a single dichotomous categorization at three weeks, which
asked patients: ‘‘Over the past week have you had adequate relief of
your IBS symptoms?’’ Regression model parameters included: COMT
genotype (number of met alleles), treatment arm and their interaction
(COMT genotype x treatment arm). Error bars are standard error of the
mean. N=102.
doi:10.1371/journal.pone.0048135.g003
Figure 1. Effect of COMT genotype on change in IBS-SSS.
Number of val158met met alleles showed a significant linear effect on
IBS-SSS (beta=0.17; p=.032). IBS-SSS includes abdominal pain severity,
abdominal pain frequency, abdominal distention severity, dissatisfac-
tion with bowel habits, and disruption of quality of life. Change in IBS-
SSS = (IBS-SSS at baseline – IBS-SSS at 3-weeks). Regression model
included COMT genotype (number of met alleles) and baseline IBS-SSS.
Error bars indicate the standard error of the mean. N=104.
doi:10.1371/journal.pone.0048135.g001
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[40]. However the involvement of the amygdala and these two
serotonin-related enzymes suggests that these associations may be
unique to SAD and not necessarily generalizable to the placebo
response mechanism. Furthermore in the absence of a no-
treatment control that would have allowed a clear separation
between placebo effects and such phenomenon as regression to the
mean, spontaneous remission or the natural waxing and waning of
illness, these studies could not rule out whether their findings were
a result of a genuine psychobiological process or merely
improvement that would have happened without placebo treat-
ment.
Four other placebo-controlled studies designed to examine the
effects of tolcapone, a COMT inhibitor, looked at the association
between COMT val158met genotype, cognition and information
processing [42,43,44,45]. Mentioned en passant in their reports was
the observation that the met/met subjects had a statistically
significant placebo effect, whereas the val/val subjects were
unresponsive to placebo treatment. Although this research
paradigm is distinctly different from IBS, these findings support
our hypothesis and suggest that the COMT mediated placebo
response pathway might be generalizable across multiple condi-
tions. Nonetheless, other replications of our study that prospec-
tively hypothesize a COMT involvement with placebo effects and
include a no treatment control will be critical to confirm our
findings.
Positioned at the intersection of catecholamine metabolism,
memory [46], reward processing [47], confirmation bias [15] and
pain regulation [16], COMT presents an interesting candidate for
a placebo response marker. The inverted U-shaped dopamine
response curve, reported in many COMT functional studies
suggests a narrow range for optimum dopamine cortical function
[48,49]. One might therefore hypothesize that drugs that interfere
with the dopaminergic pathway might affect the observed response
to treatment by shifting the component of the treatment response
resultant from placebo. Indeed several studies that examine the
effect of amphetamine [41] or tolcapone [42,43,44,45] relative to a
placebo treatment have observed that met/met subjects tend be
unresponsive or worsen relative to placebo response when treated
with these drugs, suggesting there is an optimum level of dopamine
associated with placebo effect. Identifying biological characteristics
of placebo responders and non-responders could be key to
managing underlying placebogenic factors to benefit patients by
delivering personalized medicine, for example by adjusting the
dose of medication in accordance to the subject’s placebo
susceptibility or selecting a different class of drugs for the
individualized patient.
Our study illuminates the persistent failure to identify reliable
characteristics of placebo responders [50,51,52]. Beyond using a
no-treatment control another unique feature of our study was the
inclusion of an augmented therapeutic relationship. The thera-
peutic relationship is considered an active component of non-
specific placebo treatment [30]; its presence may be needed to
identify reliable predictors of the placebo effect [53]. Prior studies
did not include an arm in which the placebo was administered
within the context of an augmented therapeutic relationship.
Indeed, many of these studies were done with volunteer subjects in
experimental rather than clinical contexts in which there was no
therapeutic relationship at all. Although this unique design of our
study is an asset, it also poses a limitation on using other studies to
retrospectively validate our findings, as most clinical trials do not
include a no-treatment control. Another limitation of this study is
its small sample size and the absence of a power calculation. Given
that our study was a secondary data analysis of an existing dataset,
the sample size was already fixed. Although a small sample size
increases the risk of a type II error (failing to find a significant
difference that exists in the population), it does not challenge the
validity of results showing significant effects. Hence, our results
deriving from a clear hypothesis are still reliable.
It is unlikely that a single locus like COMT, fully accounts for a
complex behavioral phenotype like placebo response. However,
given that COMT val158met is a functional polymorphism, which
results in a three to four-fold reduction in prefrontal dopamine, it
has a greater potential to contribute to behavioral variability than
other non-functional or noncoding polymorphisms. That COMT
has been implicated in multiple disorders i.e. major depressive
disorder, Parkinson’s and pain, might be deemed as a weakness in
its candidacy for a placebo response marker. However we argue
that this wide association with disease and drug treatments might
be why it is such a powerful potential target for modulating
placebo effects.
IBS is a functional condition characterized by a diversity of
symptoms measured by subjective instruments, which also poses
another limitation to our study. It should be noted though, that
placebo treatment is especially thought to influence the experience
and perception of subjective symptoms such as depressed mood
and pain, rather than directly modifying disease pathophysiology
[54,55].
Finally, the power of the patient-doctor interaction to enhance
healing is one of the hallmarks of clinical medicine, and
increasingly resources are devoted to teaching clinicians how to
communicate warmth and caring to their patients [56,57]. Our
findings reinforce this healing benefit for met/met patients and
raise an interesting question. Despite their best efforts, many a
warm and caring physician has had patients that seemed to derive
minimum benefit from their empathic attentions. Our findings
that val/val patients are less influenced by the placebo treatment,
regardless of whether it is delivered in an augmented or limited
context, potentially shed some light on this clinical challenge.
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